Nivolumab plus Ipilimumab Vs Platinum-Based CT plus Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial

被引：0

作者：

Delmonte, A. ^{[1
]}

Bonanno, L. ^{[2
]}

Landi, L. ^{[3
]}

Andrikou, K. ^{[1
]}

Dal Maso, A. ^{[2
]}

Minuti, G. ^{[3
]}

Papi, M. ^{[4
]}

Metro, G. ^{[5
]}

Attili, I. ^{[6
]}

Piantedosi, F. ^{[7
]}

Pilotto, S. ^{[8
]}

Gori, S. ^{[9
]}

Rossi, G. ^{[10
]}

Buglioni, S. ^{[3
]}

Giannarelli, D. ^{[11
]}

Cappuzzo, F. ^{[3
]}

机构：

[1] Ist Romagnolo Studio Tumori Dino Amadori, IRCCS, Meldola, Italy

[2] Ist Oncolog Veneto, IRCCS, Padua, Italy

[3] Natl Canc Inst, Rome, Italy

[4] Osped Infermi Rimini, Azienda Osped, Rimini, Italy

[5] Osped Santa Maria Misericordia, Azienda Osped Perugia, Perugia, Italy

[6] Ist Europeo Oncol, IRCCS, Milan, Italy

[7] Azienda Osped Colli Monaldi, Naples, Italy

[8] Azienda Osped Univ Integrata Verona, Verona, Italy

[9] Osped Sacro Cuore Don Calabria Hosp Negrar, IRCCS, Negrar, Italy

[10] Azienda AUSL Romagna, Ravenna, Italy

[11] Fdn Policlin Univ Gemelli, IRCCS, Rome, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

Immunotherapy; Nivolumab; Squamous cell carcinoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP08.01-03

引用

页码：S351 / S351

页数：1

共 50 条

[1] Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial
Landi, L.
Bonanno, L.
Delmonte, A.
Maximilian, P.
Stati, V.
Minotti, V.
Bennati, C.
D'Inca, F.
Migliorino, M. R.
Gori, S.
Santo, A.
Piantedosi, F.
Russo, A.
Cappuzzo, F.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[2] Nivolumab Plus Ipilimumab (NI) Versus Chemotherapy Plus Nivolumab (CN) in Squamous Cell Lung Cancer (SqCLC): The SQUINT Trial
Landi, L.
Bonanno, L.
Delmonte, A.
Papi, M.
Stati, V.
Minotti, V.
Bennati, C.
D'Inca, F.
Migliorino, M.
Gori, S.
Santo, A.
Piantedosi, F.
Russo, A.
Cappuzzo, F.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S727 - S727
[3] Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma
Hindson, Jordan
[J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (04) : 216 - 216
[4] Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma
Jordan Hindson
[J]. Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 216 - 216
[5] New drug approval: Nivolumab plus Ipilimumab/chemotherapy in esophageal squamous-cell carcinoma
Chalah, Celine
Neuzillet, Cindy
[J]. BULLETIN DU CANCER, 2022, 109 (10) : 990 - 991
[6] Nivolumab plus ipilimumab in advanced renal-cell carcinoma
Gunjur, Ashray
[J]. LANCET ONCOLOGY, 2018, 19 (05): : E232 - E232
[7] Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma
Gao, Jianjun
Karam, Jose A.
Wood, Christopher G.
Matin, Surena
Ahrar, Kamran
Jonasch, Eric
Tannir, Nizar
Campell, Matthew
Ng, Chaan S.
Slack, Rebecca S.
Rao, Priya
Allison, James P.
Blando, Jorge M.
Vence, Luis M.
Basu, Sreyashi
Zhao, Hao
Chen, Tenghui
Chen, Hong
Sharma, Padmanee
[J]. CANCER RESEARCH, 2017, 77
[8] FDA Approves Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
Schuyler, Devon
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (05) : 387 - 387
[9] UNISON: Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602)
Gedye, Craig
Pook, David William
Krieger, Laurence Eliot Miles
Harris, Carole A.
Goh, Jeffrey C.
Kichenadasse, Ganessan
Gurney, Howard
Underhill, Craig
Parnis, Francis
Joshua, Anthony M.
Ferguson, Thomas
Roncolato, Felicia
Harrison, Michelle L.
Morris, Michelle Frances
Begbie, Stephen
Hovey, Elizabeth J.
George, Mathew
Prithviraj, Prashanth
Liow, Elizabeth Chien Hern
Davis, Ian D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[10] Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck
Klein, Oliver
[J]. JAMA ONCOLOGY, 2024, 10 (01) : 143 - 144

← 1 2 3 4 5 →